CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CG Oncology Inc (CGON) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline and a favorable analyst outlook, the technical indicators and insider selling trends suggest caution. Additionally, the lack of recent positive news and significant trading signals further supports a hold recommendation.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 46.059, and moving averages are converging, showing no clear trend. The stock is trading below its pivot level of 52.044, with support at 49.321 and resistance at 54.768.
Analysts have consistently raised price targets, with the most recent target at $
Promising pipeline developments, including PIVOT-006 topline data expected in 1H
Large addressable market with less competition for Creto, the company's lead candidate.
Insiders are selling, with a 1311.54% increase in selling activity over the last month.
The MACD and technical indicators suggest bearish momentum.
Gross margin dropped significantly YoY, indicating potential operational challenges.
In Q3 2025, revenue increased by 3774.42% YoY to $1.67M, and net income improved by 114.69% YoY to -$43.81M. EPS also improved by 90% YoY to -0.57. However, gross margin dropped by 94.66% YoY to 5.34%, raising concerns about profitability.
Analysts are optimistic, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The most recent target is $75, citing a large market opportunity and favorable competitive positioning for Creto, the company's lead candidate.
